Despite near universal availability of nirsevimab, only 35% of eligible children receive nirsevimab for RSV prophylaxis.

Dr. R.W. Mills, Chief Medical Officer for Nationwide Children's Hospital - Toledo, talks about what to know about RSV as kids ...

As paediatric teams across Ontario prepare for the upcoming respiratory season, Halton Healthcare is proud to share an ...

Professor Margie Danchin addresses declining childhood vaccination rates and vaccine hesitancy through trust-building ...

Children hospitalized with RSV showed higher risk for ICU admission, IMV, and supplemental oxygen than children hospitalized with COVID-19 or influenza.

Vaccinating pregnant women against respiratory syncytial virus (RSV) is linked to a 72% drop in newborns being hospitalized ...

Monoclonal antibodies (mAbs) have revolutionized medicine, providing innovative treatments for many diseases. For decades, ...

We may use terms like cold and the flu as if they are the same thing, but there are some key differences between them.

The Board of Gavi, the Vaccine Alliance this week endorsed a series of adjustments to bring Gavi’s strategy for its next five-year period (2026-2030) in line ...

Despite adequate availability of nirsevimab, only about one third of eligible children receive it for respiratory syncytial ...

Vulnerable premature babies needing extra protection against RSV will receive a long-lasting single injection of nirsevimab, ...